FIG 7.

Efficacy of XZ.700 formulated as cream or gel in a mouse model of S. aureus skin infection. (A) Representative bioluminescence images of tape-stripped mice infected with the bioluminescent S. aureus strain USA300 LAC::lux and treated with XZ.700 formulated as cream or gel (30 μg XZ.700 per mL cream or gel) or the respective vehicle controls (Veh). (B) Luminescence intensity measured over time in infected animals treated with XZ.700 (XZ) gel (left) or cream (right) or the respective vehicle controls (Veh) (n = 6). (C) S. aureus CFU counts/cm² on murine skin left untreated or undergoing various treatments as described in panels A and B 74 h after infection (n = 6). (D) Representative images showing the appearance of murine skin 74 h after infection with S. aureus and various treatments as described above.